Please login to the form below

Not currently logged in
Email:
Password:

Genzyme

This page shows the latest Genzyme news and features for those working in and with pharma, biotech and healthcare.

Sanofi exits R&D pact with Alnylam on rare disease

Sanofi exits R&D pact with Alnylam on rare disease

Sanofi and Alnylam started working together on gene-silencing therapies in 2014, with the French drugmaker’s rare disease unit Genzyme making a $700m investment in the RNA interference specialist and ... Genzyme had previously licensed rights in 2012

Latest news

More from news
Approximately 28 fully matching, plus 155 partially matching documents found.

Latest Intelligence

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Rather than assuming anything, Sanofi Genzyme took a step back and asked patients: how can we help? ... In Sanofi Genzyme’s case, it culminated in a set of briefs that were owned by the patients living with the disease.

  • Pharma deals in July 2015 Pharma deals in July 2015

    Firstly the divestment for up to $300m to Genzyme of Caprelsa (vandetanib), an orphan drug treatment for thyroid carcinoma. ... 560+. AstraZeneca / Genzyme. Acquisition of R&D. Caprelsa (vandetanib) marketed. 300.

  • Medius Deal Watch table for February 2015 Medius Deal Watch table for February 2015

    Voyager Therapeutics/ Sanofi (Genzyme). Gene therapy - Parkinson's disease, Friedreich's ataxia and Huntington's disease.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Cerdelga, an oral therapy for adult patients with Gaucher disease type 1, was developed by Genzyme and approved by the FDA in August this year.

  • Pharma deals during January 2014 Pharma deals during January 2014

    The now expanded deal grants Genzyme rights in all markets outside North America and Western Europe. ... In 2008 Genzyme gained rights to ataluren from PTC Therapeutics at a cost of $100m.

More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest appointments

More from appointments
Approximately 4 fully matching, plus 35 partially matching documents found.

Latest from PMHub

  • Lucid Group make the cut at the PMEAs 2017

    OptiMiSe: a Multichannel Learning Platform for Clinical Behaviour Change Among Multiple Sclerosis Specialist Nurses, by Sanofi Genzyme, with support from Lucid Group.

  • Create Health

    ConvaTec. DRG. Hill-Rom. Micrel. MSD. Rayner. Sanofi Genzyme. Smith &Nephew. Vagisil.

  • Lucid celebrate big wins at PMEA 2015

    Success for Lucid at PMEA 2015. Lucid group successfully supported AbbVie and Genzyme to win two awards at last night’s ceremony in London. ... And they celebrated with Genzyme after supporting them to win the award for launch excellence.

  • Lucid Group Communications Limited

    Celgene. CSL Behring. Eisai. Ferring Pharmaceuticals Ltd. Genzyme. Gilead. GlaxoSmithKline. Janssen.

  • HAVAS LYNX

    AbbVie. Alexion. Almirall. Astellas. AstraZeneca. Bayer. Eisai. Genzyme. Janssen. Kowa. Lilly.

More from PMHub
Approximately 0 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Branding Science

We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics